Tomorrow at VAM26: A closer look at Spur® Stent technology Join us tomorrow for the Vascular LIVE! Interactive Session: Rethinking BTK Treatment Approach: Insights into the Retrievable Spur Stent June 11, 2026 | 3:00–3:25 PM Main Exhibit Hall The session will feature two case-based perspectives: 1 | My Treatment Algorithm for BTK Revascularization Using Spur: A Case-Based Experience Anahita Dua, MD 2 | Clinical Application of the Spur Stent in Complex BTK Anatomy: A Procedural Perspective Patrick Muck, MD The session will highlight clinical perspectives on BTK treatment strategies and explore the role of Retrievable Scaffold Therapy (RST) in complex lesion management. Visit us at Booth #913 in the Industry Exhibition to continue the conversation with our team. Learn more about the Spur® Stent System: reflowmedical.com/spur/ #VAM26 #PAD #BTK #CLIFighter #SpurStent

We’re heading to VAM26 in Boston, June 10–13, 2026. Join Reflow Medical at Booth #913 to connect with our team and explore our portfolio for complex lesion treatment, including the Spur® Stent System and Wingman™ CTO Crossing Catheter. Don’t miss the Vascular LIVE! Interactive Session: Rethinking BTK Treatment Approach: Insights into the Retrievable Spur® Stent June 11, 2026 | 3:00–3:25 PM Main Exhibit Hall Featuring Anahita Dua, MD and Patrick Muck, MD We look forward to seeing you in Boston. #VAM26 #PAD #BTK #CLIFighter #SpurStent #SpurRST

One year after the FDA De Novo Clearance of the Spur® Stent System was announced at NCVH 2025, we were grateful to return to NCVH 2026 and continue the clinical exchange around complex BTK intervention, CLTI treatment strategies, and the evolving role of Retrievable Scaffold Therapy (RST).   Thank you to Pradeep K. Nair, MD, for showcasing the Spur® Stent System in a live case session on PAD therapy, including IVUS results showing substantial luminal expansion despite severe calcific burden.   We also recognize Ramzan Zakir, MD, for sharing the new 12-month DEEPER REVEAL data on Spur, highlighting the durable safety and efficacy of RST after predilatation in CLTI patients.   Shout out to Fadi Saab, MD, and his cath lab team for sharing a live Spur case and adding to the case-based discussion around complex BTK intervention.   A sincere thank you to NCVH, Chairman Craig Walker, MD, the faculty, fellows, and physicians for creating a strong forum for clinical exchange throughout the meeting. We were glad to welcome many of you at our booth, in the supported Fellows Course, and in discussions with our team.   Learn more about the Spur Stent System: reflowmedical.com/spur/   #NCVH2026 #CLTI #BTK #PAD #SpurStent #RST

One year ago, the Spur® Peripheral Retrievable Stent System received FDA De Novo Clearance. Today, we celebrate more than a regulatory milestone. Received during NCVH 2025, the clearance marked a defining moment for Reflow Medical. Over the past year, that milestone has become momentum: growing clinical adoption, expanding scientific evidence, and continued focus on progress in BTK disease treatment. We are deeply grateful to our clinical partners and to the Reflow Medical team who made this journey possible. Your trust, insight, commitment, and persistence continue to help bring Spur closer to the patients who need it most. Here’s to one year of FDA De Novo Clearance and to building on this momentum together. #SpurStent #DeNovo #PAD #BTK #Vascular

The stent that leaves nothing behind. The Breakthrough Device-designated Spur® offers a revolutionary approach to BTK treatment. It provides mechanical support during the procedure and leaves nothing behind. In CLTI patients with long, calcified infrapopliteal lesions, treatment with the Spur Peripheral Retrievable Stent System following predilatation demonstrated durable safety and efficacy at 12 months.* The Spur Stent System is intended for the treatment of de novo or restenotic infrapopliteal lesions following predilatation. Through mechanical scaffolding and radially expandable spikes, Spur supports the vessel wall, facilitates blood flow, and enables controlled lesion penetration and modification to improve vessel compliance and reduce recoil. Following treatment, the device is fully retrieved. Learn more about Spur and its clinical evidence: reflowmedical.com/spur/ Full U.S. Indications for Use: reflowmedical.com/resources/ *Data on file for DEEPER REVEAL clinical trial (NCT05358353). #PAD #CLTI #Endovascular #CLIFighters #SpurStent

NCVH 2026 starts today. Stop by Booth 215 at the 2026 NCVH Annual Conference to connect with our team and explore our peripheral endovascular portfolio for complex lesion treatment, including: • Spur® Peripheral Retrievable Stent System for BTK disease • Wingman™ CTO Crossing Catheter for the most challenging lesions • Spex® and Spex® LP Shapeable Support Microcatheters, customizable to a preferred angle We look forward to welcoming registered fellows today and tomorrow, May 26–27, for didactic education and cadaver-based hands-on training around devices, techniques, and therapy strategies. Learn more about our products: reflowmedical.com/all-produc… #PAD #CLTI #Endovascular #CLIFighters #NCVH2026

Late-breaking at EuroPCR 2026. And more to come. Today in Paris, Scott Harding, MD, shared the first 6-month results from the DEEPER CORONARY first-in-human study evaluating the investigational coronary Spur® Elute Sirolimus-Eluting Retrievable Stent System for coronary ISR. The results demonstrated safety and promising efficacy: • 100% freedom from MACE • 100% freedom from all-cause mortality • Improvement in CCS angina class across all treated patients For Reflow Medical, these early findings add important clinical momentum to our coronary program and support the continued evaluation of Spur Elute in coronary ISR. We thank Dr. Harding and all investigators for their excellent work. Read the full press release: reflowmedical.com/reflow-med… #EuroPCR #Cardiovascular #InterventionalCardiology #ISR #SpurElute

A first look at what may be next in coronary ISR Join Scott Harding, MD, at EuroPCR 2026 for the first-ever presentation of the 6-month first-in-human clinical results from the DEEPER CORONARY trial, evaluating the coronary Spur® Elute Sirolimus-Eluting Retrievable Stent System for the treatment of in-stent restenosis. EuroPCR 2026 | Paris, France May 20, 2026 | 11:15–12:15 Innovation Theatre Session: Coronary interventions: first-in-man and novel devices Be among the first to hear the late-breaking clinical data and follow us for more updates on this exciting journey. #EuroPCR #InterventionalCardiology #SpurElute #ReflowMedical

We are looking forward to the 2026 NCVH Annual Conference, May 26–29, in New Orleans. Visit us at Booth 215 to connect with our team and explore our endovascular portfolio for complex lesion treatment, including the Spur® Peripheral Retrievable Stent System for below-the-knee disease and the Wingman™ Catheter to cross challenging CTOs. We are also proud to support the @NCVHonline Fellows Course, May 26–27, with didactic education and cadaver-based hands-on training. A great opportunity for fellows to engage with devices, techniques, and therapy strategies. Learn more about our products: lnkd.in/gtAifsaa See you in New Orleans.

How do the latest 12-month DEEPER REVEAL trial data translate into clinical benefit in BTK CLTI? In patients with long, calcified infrapopliteal lesions, treatment with the Spur® Peripheral Retrievable Stent System following predilatation demonstrated*: • Meaningful clinical recovery • Reduced reintervention rates • Sustained vessel patency Key safety and efficacy outcomes at 12 months: • Primary patency: 78.0% • Freedom from clinically driven TLR: 83.1% • Complete paired wound healing: 84.3% • Rutherford class improvement: 80.0%] These findings highlight the potential of Retrievable Scaffold Therapy (RST) to deliver durable vessel-related and patient-centered outcomes, supporting its role in the treatment of complex BTK disease while leaving nothing behind. How do you define relevant outcomes for your CLTI patients in daily practice? 🔗 Read the full press release: reflowmedical.com/reflow-med… 🔗 Full U.S. Indications for Use: reflowmedical.com/resources/ *At 12 months, vessel-related outcomes in appropriately selected vessels (core lab-measured reference vessel diameter ≥2.5 mm, per study protocol and indication for use) and patient-centered outcomes were assessed.

RÖKO 2026 is coming up, and our team will be there to connect around complex PAD treatment. From May 13–15, 2026, Reflow Medical will be on-site at the 107th Deutscher Röntgenkongress in Leipzig. Visit us at booth CCL7 to meet our team and learn more about our vascular intervention portfolio for CTO crossing, lesion preparation, and temporary scaffolding: • Wingman™ CTO Crossing Catheter • Spur® Peripheral Retrievable Scaffold System • Spex® and Spex® LP Shapeable Support Microcatheters See you in Leipzig. #RÖKO2026 #PAD #Endovascular #InterventionalRadiology

Unmatched Spinning Freedom through a Unique Technology - Now Available in the U.S. Both Cora Flex® and Cora Force® integrate our proprietary technology Cora Tech™ which sets a new standard for torqueable coronary microcatheters. Cora Tech™ enables highest bi-directional spinning freedom and best torque transmission compared to market leaders during navigation and crossing of complex coronary lesions.* Key technology elements: • No-liner construction for unrestricted torque rotations without liner–guidewire lock-up • PTFE-coated coils for smooth guidewire advancement • Stainless steel braid for more predictable torque transmission and precise catheter control Learn more about our next-generation torqueable microcatheters: Cora Flex – For everyday complex cases: reflowmedical.com/coracathet… Cora Force – For the tough cases: reflowmedical.com/coracathet… * Data on file. Bench testing assessed rotations until loss of guidewire maneuverability as well as peak torque transmission. Refer to the Instructions for Use for a complete listing of indications, contraindications, warnings, precautions, complications, and directions for use: reflowmedical.com/resources/

Everybody needs a Wingman. When cases get tough, you want a backup you can trust. The Wingman™ CTO Crossing Catheter is designed to step in when standard tools fall short. With its unique extendable and rotating beveled needle tip, it is designed to help you cross complex CTOs, right from the occlusion cap through the true lumen. Its “push and twist” handle gives you intuitive control to anchor, penetrate, and advance the catheter through the tightest lesions. With a braid-reinforced shaft for strength and a hydrophilic coating for smooth tracking, Wingman is a partner that has been clinically proven to deliver high crossing success and shorter crossing times. Bring your Wingman when things get tough. US: reflowmedical.com/wingman/ CE: reflowmedical.com/wingman-eu… Refer to the Instructions for Use for a complete listing of Indications, Contraindications, Warnings, Precautions, Complications, and Directions for Use: reflowmedical.com/resources/

Thank you for a great Advanced Vascular Conference (AVC) 2026. We are proud to be part of such an interactive format that truly fosters open exchange and discussion. A special thank you to Prof. Dr. med. Konstantinos Donas, Prof. Erwin Blessing, and Dr. Marc Sirvent for sharing their practical insights during the BTK session, focusing on treatment strategies for complex infrapopliteal lesions, including Retrievable Scaffold Therapy (RST). These are the exchanges that challenge routines and help refine how to approach patients suffering from severe disease. #AVC2026 #BTK #CLIFighter #Spur #Wingman

#SCAI2026 marked two important highlights for Reflow Medical: the U.S. launch of the next-generation coronary torqueable microcatheters, Cora Flex® and Cora Force®, now commercially available, and a podium presentation featuring the latest 12-month DEEPER REVEAL trial data in the main session "New Approaches on the Horizon: What’s in the Pipeline." Shout out to @sahilparikhmd Sahil Parikh, MD, FSCAI, for including insights on current and future Spur® stent technologies in his presentation. To explore the 12-month DEEPER REVEAL trial data, learn more here: reflowmedical.com/reflow-med… To learn more about the Cora Flex and Cora Force, visit our website: reflowmedical.com/coracathet… Refer to the Instructions for Use for a complete listing of the Indications, Contraindications, Warnings, Precautions, Complications, and Directions for Use for Cora Flex, Cora Force, and Spur: reflowmedical.com/resources/ #InterventionalCardiology #CoraFlex #CoraForce #SpurStent

A strong start in Marbella, Spain bringing together guest physicians from across Europe for the first Physician Proctor Training with @PalenaMariano Mariano Palena, MD, Elisa Piccolo, MD and Fernando Gallardo, MD. The program focused on real-world CLTI BTK treatment, combining live cases with open discussion and hands-on decision making in the cath lab, creating a highly interactive learning environment. We believe advancing CLTI treatment requires more than innovation alone. Learning by doing and direct exchange with experienced physicians are key to translating new technologies into clinical practice. #pad #clti #btk #endovascular

Three years of Spur® in conjunction with DCB. Sustained strong outcomes, growing clinical evidence in BTK. At Charing Cross 2026, the @CXSymposium, our study spotlight was clear: DEEPER OUS 3-year data were presented by Andrew Holden, MD, for the first time on the main podium, demonstrating sustained safety and clinical efficacy of the Spur Peripheral Retrievable Scaffold System in combination with paclitaxel DCBs after predilatation. These findings represent an important step in the ongoing development of clinical evidence for Spur in BTK lesions. A sincere thank you to @AnahitaDua, MD, Leyla Schweiger, MD, and Bruno Migliara, MD for their valuable contributions and clinical perspectives on Retrievable Scaffold Therapy (RST) throughout the sessions. We look forward to seeing you again next year. For the complete Spur CE Instructions for Use, including a full listing of indications, contraindications, warnings, precautions, complications, and directions for use, please visit: reflowmedical.com/resources/ #CLTI #BTK #vascular #CX2026 #Spur